‘Cancer Prevention Must Move From Thought to Reality’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 2
Volume 11
Issue 2

WASHINGTON-"Cancer prevention now requires that we move from thought to reality," said Carolyn Aldigé, founder and president of the Cancer Research Foundation of America (CRFA). "This mean a new paradigm of the health care system, rather than just taking care of sick people. Treatment of advanced disease has less impact than prevention."

WASHINGTON—"Cancer prevention now requires that we move from thought to reality," said Carolyn Aldigé, founder and president of the Cancer Research Foundation of America (CRFA). "This mean a new paradigm of the health care system, rather than just taking care of sick people. Treatment of advanced disease has less impact than prevention."

The Foundation has sponsored the Cancer Prevention Working Group, which has spent 2 years framing the issues and outlining challenges, she said at a meeting of the Working Group. "Now we need to formulate an action plan to take concrete steps. We must engage regulators and the primary care community and convince them that prevention is important," she said.

Ms. Aldigé said that such a plan could be devised within a year, taking the best current practices and research and weaving them into a broad cancer prevention approach.

She called for a summit meeting in the interim to deal with specific issues and barriers, especially questions of approval, regulation, and liability. The keys, she said, are further research to identify chemopreventive agents and devising ways to provide incentives to the pharmaceutical industry.

Recent Videos
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Two experts are featured in this series.
Two experts are featured in this series.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
2 experts are featured in this series.
2 experts are featured in this series.
Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Related Content